Advertisement

Journal of Neural Transmission

, Volume 123, Issue 1, pp 45–50 | Cite as

Psychosis in Parkinson’s disease: identification, prevention and treatment

  • Johannes  Levin
  • Alkomiet  Hasan
  • Günter  U. Höglinger
Neurology and Preclinical Neurological Studies - Review Article

Abstract

Psychosis in Parkinson’s disease (PD) is a frequent condition affecting >20 % of all PD patients. It is characterized by vivid dreams, nightmares, illusions, delusions and mostly visual hallucinations. Typically psychosis occurs in the late stage of PD, affecting up to 70 % of the patients following a disease duration of 20 years or more, and can severely interfere with the care of the patients, especially if the patients develop delusions. Psychosis is the principal cause of admission to a nursing home for PD patients. Hence, preemptive identification of risk factors, and avoidance and elimination of triggers are most important measures against psychosis in PD patients. Secondarily, pharmaceutical measures are being undertaken successively, including simplification of medication regimes, discontinuation of non-essential CNS-active drugs, ordered reduction of antiparkinsonian drugs, addition of cholesterinase inhibitors in cognitively impaired patients, and finally addition of antipsychotic medication with limited parkinsonian side effects. As psychosis in PD is a frequent and important problem, we set out to write a state-of-the-art guideline for its identification and treatment.

Keywords

Parkinson’s disease Psychosis Hallucination Dopamine 

Notes

Acknowledgments

G. Höglinger is funded by the Deutsche Forschungsgemeinschaft (DFG, HO2402/6-2). We wish to thank Katie Ogston for editing the manuscript.

Conflict of interest

Höglinger GU received speaker honoraria and travel support from Abbvie, Roche, and UCB; and compensation for scientific advisory board activity for Bristol-Myers Squibb, Roche, Sellas, and UCB. Hasan A has been invited to scientific meetings by Lundbeck, Janssen-Cilag, and Pfizer, and he received paid speakership by Desitin, Otsuka and BAK. He was member of the Roche Advisory Board.

References

  1. Bizzarri JV, Giupponi G, Maniscalco I, Schroffenegger P, Conca A, Kapfhammer HP (2015) Parkinson’s disease and psychoses. Neuropsychiatr. (Epub ahead of print)Google Scholar
  2. Carod-Artal FJ, Mesquita HM, Ziomkowski S, Martinez-Martin P (2013) Burden and health-related quality of life among caregivers of Brazilian Parkinson’s disease patients. Parkinsonism Relat Disord 19:943–948. doi: 10.1016/j.parkreldis.2013.06.005 PubMedCrossRefGoogle Scholar
  3. Chaudhuri KR, Martinez-Martin P, Brown RG, Sethi K, Stocchi F, Odin P, Ondo W, Abe K, Macphee G, Macmahon D, Barone P, Rabey M, Forbes A, Breen K, Tluk S, Naidu Y, Olanow W, Williams AJ, Thomas S, Rye D, Tsuboi Y, Hand A, Schapira AH (2007) The metric properties of a novel non-motor symptoms scale for Parkinson’s disease: results from an international pilot study. Mov Disord 22:1901–1911PubMedCrossRefGoogle Scholar
  4. Connolly BS, Lang AE (2014) Pharmacological treatment of Parkinson disease: a review. JAMA 311:1670–1683. doi: 10.1001/jama.2014.3654 PubMedCrossRefGoogle Scholar
  5. Cummings J, Isaacson S, Mills R, Williams H, Chi-Burris K, Corbett A, Dhall R, Ballard C (2014) Pimavanserin for patients with Parkinson’s disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet 383:533–540. doi: 10.1016/S0140-6736(13)62106-6 PubMedCrossRefGoogle Scholar
  6. Fernandez HH, Aarsland D, Fénelon G, Friedman JH, Marsh L, Tröster AI, Poewe W, Rascol O, Sampaio C, Stebbins GT, Goetz CG (2008) Scales to assess psychosis in Parkinson’s disease: critique and recommendations. Mov Disord 23:484–500. doi: 10.1002/mds.21875 PubMedCrossRefGoogle Scholar
  7. Friedman JH (2011) Atypical antipsychotic drugs in the treatment of Parkinson’s disease. J Pharm Pract 24:534–540. doi: 10.1177/0897190011426556 PubMedCrossRefGoogle Scholar
  8. Gama RL, de Bruin VM, de Bruin PF, Távora DG, Lopes EM, Jorge IF, Bittencourt LR, Tufik S (2015) Risk factors for visual hallucinations in patients with Parkinson’s disease. Neurol Res 37:112–116. doi: 10.1179/1743132814Y.0000000418 PubMedCrossRefGoogle Scholar
  9. Godschalx-Dekker JA, Siegers HP (2014) Reduction of parkinsonism and psychosis with mirtazapine: a case report. Pharmacopsychiatry 47:81–83. doi: 10.1055/s-0034-1367014 PubMedCrossRefGoogle Scholar
  10. Goetz CG, Stebbins GT (1993) Risk factors for nursing home placement in advanced Parkinson’s disease. Neurology 43:2227–2229PubMedCrossRefGoogle Scholar
  11. Goetz CG, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stebbins GT, Stern MB, Tilley BC, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, Van Hilten JJ, LaPelle N (2007) Movement Disorder Society-sponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS): process, format, and clinimetric testing plan. Mov Disord 22:41–47PubMedCrossRefGoogle Scholar
  12. Goldman JG, Holden S (2014) Treatment of psychosis and dementia in Parkinson’s disease. Curr Treat Options Neurol 16:281. doi: 10.1007/s11940-013-0281-2 PubMedPubMedCentralCrossRefGoogle Scholar
  13. Hack N, Fayad SM, Monari EH, Akbar U, Hardwick A, Rodriguez RL, Malaty IA, Romrell J, Shukla AA, McFarland N, Ward HE, Okun MS (2014) An eight-year clinic experience with clozapine use in a Parkinson’s disease clinic setting. PLoS ONE 9(3):e91545. doi: 10.1371/journal.pone.0091545 PubMedPubMedCentralCrossRefGoogle Scholar
  14. Hasan A, Falkai P, Wobrock T, Lieberman J, Glenthoj B, Gattaz WF, Thibaut F, Möller HJ, World Federation of Societies of Biological Psychiatry (WFSBP) Task Force on Treatment Guidelines for Schizophrenia (2012) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 1: update 2012 on the acute treatment of schizophrenia and the management of treatment resistance. World J Biol Psychiatry 13:318–378PubMedCrossRefGoogle Scholar
  15. Hassan A, Wu SS, Schmidt P, Dai Y, Simuni T, Giladi N, Bloem BR, Malaty IA, Okun MS, Investigators NPF-QII (2013) High rates and the risk factors for emergency room visits and hospitalization in Parkinson’s disease. Parkinsonism Relat Disord 19:949–954. doi: 10.1016/j.parkreldis.2013.06.006 PubMedCrossRefGoogle Scholar
  16. Howes OD, Kapur S (2009) The dopamine hypothesis of schizophrenia: version III—the final common pathway. Schizophr Bull 35(3):549–562. doi: 10.1093/schbul/sbp006 PubMedPubMedCentralCrossRefGoogle Scholar
  17. Kapur S, Seeman P (2001) Does fast dissociation from the dopamine d(2) receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158:360–369PubMedCrossRefGoogle Scholar
  18. Lee AH, Weintraub D (2012) Psychosis in Parkinson’s disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord 27:858–863. doi: 10.1002/mds.25003 PubMedPubMedCentralCrossRefGoogle Scholar
  19. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM (2013) Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382:951–962. doi: 10.1016/S0140-6736(13)60733-3 PubMedCrossRefGoogle Scholar
  20. Li Z, Ichikawa J, Huang M, Prus AJ, Dai J, Meltzer HY (2005) ACP-103, a 5-HT2A/2C inverse agonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens. Psychopharmacology 183:144–153PubMedCrossRefGoogle Scholar
  21. Lutz UC, Sirfy A, Wiatr G, Altpass D, Farger G, Gasser T, Karle KN, Batra A (2014) Clozapine serum concentrations in dopamimetic psychosis in Parkinson’s disease and related disorders. Eur J Clin Pharmacol 70:1471–1476. doi: 10.1007/s00228-014-1772-0 PubMedCrossRefGoogle Scholar
  22. Meltzer HY, Huang M (2008) In vivo actions of atypical antipsychotic drug on serotonergic and dopaminergic systems. Prog Brain Res 172:177–197. doi: 10.1016/S0079-6123(08)00909-6 PubMedCrossRefGoogle Scholar
  23. Meltzer HY, Elkis H, Vanover K, Weiner DM, van Kammen DP, Peters P, Hacksell U (2012) Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2 mg/day, but does not enhance efficacy of haloperidol, 2 mg/day: comparison with reference dose risperidone, 6 mg/day. Schizophr Res 141:144–152. doi: 10.1016/j.schres.2012.07.029 PubMedCrossRefGoogle Scholar
  24. Perry EK, Marshall E, Kerwin J, Smith CJ, Jabeen S, Cheng AV, Perry RH (1990) Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J Neurochem 55(4):1454–1456PubMedCrossRefGoogle Scholar
  25. Rodríguez-Violante M, Cervantes-Arriaga A, Velázquez-Osuna S, Llorens-Arenas R, Calderón-Fajardo H, Piña-Fuentes D, Martinez-Martin P (2014) Independent Validation of the SEND-PD and Correlation with the MDS-UPDRS Part IA. Parkinsons Dis 2014:260485. doi: 10.1155/2014/260485 PubMedPubMedCentralGoogle Scholar
  26. Sawada H, Oeda T (2013) Protocol for a randomised controlled trial: efficacy of donepezil against psychosis in Parkinson’s disease (EDAP). BMJ Open 3:e003533. doi: 10.1136/bmjopen-2013-003533 PubMedPubMedCentralCrossRefGoogle Scholar
  27. Sawada H, Oeda T, Yamamoto K, Umemura A, Tomita S, Hayashi R, Kohsaka M, Kawamura T (2013) Trigger medications and patient-related risk factors for Parkinson disease psychosis requiring anti-psychotic drugs: a retrospective cohort study. BMC Neurol 13:145. doi: 10.1186/1471-2377-13-145 PubMedPubMedCentralCrossRefGoogle Scholar
  28. Seppi K, Weintraub D, Coelho M, Perez-Lloret S, Fox SH, Katzenschlager R, Hametner EM, Poewe W, Rascol O, Goetz CG, Sampaio C (2011) The Movement Disorder Society Evidence-Based Medicine Review Update: treatments for the non-motor symptoms of Parkinson’s disease. Mov Disord 26(Suppl 3):S42–S80. doi: 10.1002/mds.23884 PubMedPubMedCentralCrossRefGoogle Scholar
  29. Ueda S, Koyama K, Okubo Y (2010) Marked improvement of psychotic symptoms after electroconvulsive therapy in Parkinson disease. J ECT 26:111–115. doi: 10.1097/YCT.0b013e3181c18a3d PubMedCrossRefGoogle Scholar
  30. Usui C, Hatta K, Doi N, Kubo S, Kamigaichi R, Nakanishi A, Nakamura H, Hattori N, Arai H (2011) Improvements in both psychosis and motor signs in Parkinson’s disease, and changes in regional cerebral blood flow after electroconvulsive therapy. Prog Neuropsychopharmacol Biol Psychiatry 35:1704–1708. doi: 10.1016/j.pnpbp.2011.05.003 PubMedCrossRefGoogle Scholar
  31. Voss T, Bahr D, Cummings J, Mills R, Ravina B, Williams H (2013) Performance of a shortened Scale for Assessment of Positive Symptoms for Parkinson’s disease psychosis. Parkinsonism Relat Disord 19:295–299. doi: 10.1016/j.parkreldis.2012.10.022 PubMedCrossRefGoogle Scholar
  32. Weintraub D, Chen P, Ignacio RV, Mamikonyan E, Kales HC (2011) Patterns and trends in antipsychotic prescribing for Parkinson disease psychosis. Arch Neurol 68:899–904. doi: 10.1001/archneurol.2011.139 PubMedPubMedCentralCrossRefGoogle Scholar
  33. Whitehouse PJ (1987) Clinical and neurochemical consequences of neuronal loss in the nucleus basalis of Meynert in Parkinson’s disease and Alzheimer’s disease. Adv Neurol 45:393–397PubMedGoogle Scholar
  34. Wolters EC (1999) Dopaminomimetic psychosis in Parkinson’s disease patients: diagnosis and treatment. Neurology 52(7 Suppl 3):S10–S13PubMedGoogle Scholar

Copyright information

© Springer-Verlag Wien 2015

Authors and Affiliations

  • Johannes  Levin
    • 1
  • Alkomiet  Hasan
    • 2
  • Günter  U. Höglinger
    • 3
    • 4
  1. 1.Department of NeurologyLudwig-Maximilians-UniversitätMunichGermany
  2. 2.Department of Psychiatry and PsychotherapyLudwig-Maximilians-UniversitätMunichGermany
  3. 3.Department of NeurologyTechnische Universität MünchenMunichGermany
  4. 4.Department of Translational NeurodegenerationGerman Center for Neurodegenerative Diseases (DZNE) MunichMunichGermany

Personalised recommendations